Clinical Trial Update: Efficacy, Safety and Tolerability of AEB071 in Patients With Active, Moderate to Severe Ulcerative Colitis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on AEB071 in active, moderate to severe ulcerative colitis assessing efficacy, safety, and tolerability.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• AEB071 (sotrastaurin)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Ulcerative Colitis | Phase 2 | Status: COMPLETED